Proton Pump Inhibiters Promote Acid Rebound Effects

Friday, 09 September 2011 by | Comments: 1
Reading Time: 2 minutes

Diagram depicting the major determinants of gastric acid secretion, with inclusion of drug targets for peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).

Many millions of people are currently prescribed proton pump inhibitors (PPI’s) to manage excess acid production in the stomach. There are many disease and adverse health related outcomes linked to people taking PPI’s.

The associations of fractures of hip, wrist, forearm and other sites appear weak and only slightly higher than the risks in control populations matched for age. They may increase with drug exposure, but probably do so only in individuals in whom other risk factors are also operational (smoking, alcohol, poor nutrition, steroids, etc.).

Reading Time: 3 minutes

At first sight one may wonder why a paper published in the British Journal of Clinical Pharmacology is being highlighted on this web site.[1] Yet Dr Guiney and his colleagues have evolved a very elegant approach to complex metabolically relevant data collection using a simple, non-invasive test that should be celebrated as an example a combination of science, economics and human/animal care, sometimes assumed not to exist in large research establishments. This paper expanded on a previous study published in 2010.[2]